Compare SABS & NOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | NOA |
|---|---|---|
| Founded | 2014 | 1953 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 349.9M |
| IPO Year | 2020 | 2006 |
| Metric | SABS | NOA |
|---|---|---|
| Price | $3.09 | $12.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $11.64 | ★ $18.35 |
| AVG Volume (30 Days) | ★ 477.0K | 87.3K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 2.87% |
| EPS Growth | ★ 78.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.28 |
| Revenue Next Year | N/A | $10.17 |
| P/E Ratio | ★ N/A | $18.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.97 | $11.93 |
| 52 Week High | $5.15 | $17.26 |
| Indicator | SABS | NOA |
|---|---|---|
| Relative Strength Index (RSI) | 31.73 | 28.76 |
| Support Level | N/A | N/A |
| Resistance Level | $4.02 | $13.94 |
| Average True Range (ATR) | 0.16 | 0.30 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 8.99 | 0.00 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.